Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Fondazione Italiana Linfomi ONLUS
ClinicalTrials.gov Identifier:
NCT01478269
First received: October 12, 2011
Last updated: November 22, 2011
Last verified: November 2011

October 12, 2011
November 22, 2011
May 2009
May 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01478269 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy

B-Cell Lymphomas
Not Provided
Cases of aggressive B-cell lymphoma
Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1927
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007.
  2. Any stage of disease.
  3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
  4. Age at least 18 years.
  5. Availability of tissue biopsy at diagnosis for a possible centralized revision.
  6. Availability of data on clinical involvement, laboratory, treatment and follow up.

Exclusion Criteria:

  • None
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Brazil,   Italy
 
NCT01478269
IIL_ProDLBCL
No
Fondazione Italiana Linfomi ONLUS
Fondazione Italiana Linfomi ONLUS
Not Provided
Study Director: Massimo Federico, MD Oncologia II Azienda Ospedaliera Universitaria di Modena
Principal Investigator: Stefano Luminari, MD Oncologia II Azienda Ospedaliera Universitaria di Modena
Fondazione Italiana Linfomi ONLUS
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP